ArticleBMC cardiovascular disorders2025
Stress hyperglycemia ratio and its correlation with long-term prognosis in ACS patients with chronic kidney disease: a retrospective study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Stress hyperglycemia ratio in coronary artery disease: a systematic review and meta-analysis of severity and prognosis.Cardiovascular diabetology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe Stress Hyperglycemia Ratio (SHR), which serves as an indicator of blood glucose variability in response to acute illness or injury, has been established as a predictor of long-term prognosis for various diseases, particularly those affecting cardiovascular health. However, the relationship between SHR and patients presenting with acute coronary syndrome (ACS) in conjunction with chronic kidney disease (CKD) remains to be fully elucidated.
methodsFrom January 2013 to December 2019, this study enrolled a total of 465 patients with ACS complicated by CKD at the First Affiliated Hospital of Wenzhou Medical University. Fasting blood glucose (FBG), glycated hemoglobin, and other relevant parameters were recorded for these patients, and they were followed up for major adverse cardiovascular events (MACE).
resultsA total of 465 patients were ultimately included, of whom 97 experienced MACE during the follow-up period. Multivariate Cox regression analysis revealed that SHR is an independent risk factor for patients with ACS complicated by CKD. The group with elevated SHR exhibited the highest incidence of MACE, and a nonlinear "J-shaped" relationship was observed between SHR and the risk of MACE, with an inflection point at 0.84. However, no significant heterogeneity was noted in the subgroup analysis. The inclusion of SHR enhances the predictive capability of the GRACE score.
conclusionSHR serves as a reliable indicator of long-term outcomes in patients with ACS and CKD. Additionally, SHR enhances the prognostic accuracy of the GRACE score for ACS-CKD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.